ArticleCancer research2021
Acquired
Open access · bronzeAbstract read
In one paragraph
Article in Cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.
0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed
5.6field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 83 citations in OpenAlex.
- Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial.British journal of cancer · 2026Trial
- Distinct functions of mammalian RAD51 paralogs in genome maintenance.Biochemical Society transactions · 2026Review
- Smyca-FOXM1 ribonucleoprotein complex promotes homologous recombination and tumor immune evasion to define a therapeutic target of triple-negative breast cancer.Journal of biomedical science · 2026Article
- Decoding PARP roles in breast cancer therapy resistance.Molecular biology reports · 2026Review
- Context-dependent synthetic lethality - an emerging precision therapeutic approach.Nature reviews. Cancer · 2026Review
- HRR gene promoter methylation-guided nomogram predicts PARP inhibitor efficacy and progression-free survival in high-grade serous ovarian cancer.Clinical epigenetics · 2026Article
- Adaptive therapy: a balanced triangle for chronic cancer management.Journal of the National Cancer Center · 2026Article
- Cancer genomic profiling predicts pathogenicity ofmedRxiv : the preprint server for health sciences · 2026Article
- PDMSA: A Web-Based Tool for Pan-Cancer Survival Analysis Using DNA Methylation Levels as Biomarkers.Advanced genetics (Hoboken, N.J.) · 2026Article
- Metastatic Triple Negative Breast Cancer: Navigating a Rapidly Evolving Therapeutic Landscape.Oncology research · 2026Review
- DNA Methylation in Ovarian and Endometrial Cancers: Predictive and Mechanistic Roles in PARP Inhibitor and ICI Response.Cancer science · 2025Review
- A Novel Droplet Digital PCR Assay for BRCA1 and RAD51C Methylation: Advancing Homologous Recombination Deficiency Detection in Ovarian Cancer.The Journal of molecular diagnostics : JMD · 2025Article
- PRMT5 regulates alternative splicing of TCF3 under hypoxia to promote EMT and invasion in breast cancer.PLoS biology · 2025Article
- A DNA alteration and methylation co-detection method for clinical purpose.EMBO molecular medicine · 2025Article
- Clinical approaches to overcome PARP inhibitor resistance.Molecular cancer · 2025Review
- DNA repair and the contribution to chemotherapy resistance.Genome medicine · 2025Review
- Antitumor activity of rucaparib plus PLX038A in serous endometrial carcinoma.Journal of experimental & clinical cancer research : CR · 2025Article
- Epigenetic Therapies in Melanoma-Targeting DNA Methylation and Histone Modification.Biomedicines · 2025Review
- Perspectives on cancer therapy-synthetic lethal precision medicine strategies, molecular mechanisms, therapeutic targets and current technical challenges.Cell death discovery · 2025Review
- Genomics of ovarian cancers and the potential of precision medicine.Therapeutic advances in medical oncology · 2025Review
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 10 institutions in 2 countries.
Ksenija Nesic *The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
Olga Kondrashova *The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.ORCID 0000-0003-0022-5149
Rachel M HurleyDepartments of Oncology and Molecular Pharmacology, Mayo Clinic, Rochester, Minnesota.
Cordelia D McGeheeDepartments of Oncology and Molecular Pharmacology, Mayo Clinic, Rochester, Minnesota.
Cassandra J VandenbergThe Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
Gwo-Yaw HoThe Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.ORCID 0000-0003-1195-2296
Elizabeth LieschkeThe Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
Genevieve DallThe Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
Nirashaa BoundThe Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
Kristy Shield-ArtinThe Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
Marc RadkeUniversity of Washington, Seattle, Washington.
Ashan MusaferOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia.
Zi Qing ChaiOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia.
Mohammad Reza Eftekhariyan GhamsariOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia.ORCID 0000-0003-3531-3042
Maria I HarrellUniversity of Washington, Seattle, Washington.
Damien KeeThe Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.ORCID 0000-0002-4685-1666
Inger OlesenThe Andrew Love Cancer Centre, Barwon Health, Geelong, Victoria, Australia.
Orla McNallySir Peter MacCallum Cancer Centre Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
Nadia TraficanteSir Peter MacCallum Cancer Centre Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
Australian Ovarian Cancer Study
Anna DeFazioCentre for Cancer Research, The Westmead Institute for Medical Research, Sydney, NSW, Australia.ORCID 0000-0003-0057-4744
David D L BowtellSir Peter MacCallum Cancer Centre Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
Elizabeth M SwisherUniversity of Washington, Seattle, Washington.ORCID 0000-0003-2331-0434
S John WerohaDepartments of Oncology and Molecular Pharmacology, Mayo Clinic, Rochester, Minnesota.
Katia NonesQIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.ORCID 0000-0003-1925-5196
Nicola WaddellQIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.ORCID 0000-0002-3950-2476
Scott H KaufmannDepartments of Oncology and Molecular Pharmacology, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-4900-7145
Alexander Dobrovic *Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia.ORCID 0000-0003-3414-112X
Matthew J Wakefield *The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.ORCID 0000-0001-6624-4698
Clare L Scott *The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia. scottc@wehi.edu.au.ORCID 0000-0002-3689-5956
The University of Melbourne · AUMayo Clinic · USOlivia Newton-John Cancer Wellness & Research Centre · AUUniversity of Washington · USPeter MacCallum Cancer Centre · AUQIMR Berghofer Medical Research Institute · AURoyal Women's Hospital · AUWalter and Eliza Hall Institute of Medical Research · AUBarwon Health · AUThe University of Sydney · AU
Funding
Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI Zhenkun Lou · 2009 to 2026
$37.0MVaccinating against IGFBP-2 to prevent ovarian cancer relapseP50CA083636 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI DRESCHER, CHARLES, URBAN, NICOLE DENISE · 1999 to 2015
$35.1MPredoctoral Training Program in Molecular PharmacologyT32GM072474 · NIGMS · MAYO CLINIC ROCHESTER · PI KARNITZ, LARRY M · 2005 to 2020
$2.4MA Systems Biology Approach to Mechanisms of PARP Inhibitor Resistance in Ovarian CancerF30CA213737 · NCI · MAYO CLINIC ROCHESTER · PI MCGEHEE, CORDELIA · 2017 to 2021
$190kNCI NIH HHS F30 CA213737NCI NIH HHS P50 CA083636NCI NIH HHS P50 CA136393NIGMS NIH HHS T32 GM072474
Abstract
In high-grade serous ovarian carcinoma (HGSC), deleterious mutations in DNA repair gene
Indexed as
DNA MethylationPromoter Regions, GeneticAnimalsAntineoplastic AgentsCell Line, TumorComputational BiologyCystadenocarcinoma, SerousDisease Models, AnimalDNA-Binding ProteinsDrug Resistance, NeoplasmFemaleGene Expression ProfilingGene SilencingHomozygoteHumansMiceAntineoplastic AgentsDNA-Binding ProteinsPoly(ADP-ribose) Polymerase InhibitorsRAD51C protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.